Clinical trial
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV…
NCT00281541 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00281541 |
|---|---|
| Title | A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma |
| Official title | A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | YM155 |
| Enrollment | 29 |
| Start date | Nov 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Jan 25, 2006 |
| Last update posted | Jun 7, 2012 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: